Edwards Lifesciences (NYSE:EW) today announced its plans for significant growth as a purely structural heart company in 2025.

FY24 consensus $5.83B. “It is an exciting day for Edwards as we share our vision for 2025 and how our talented team and focus in structural ...

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, ...

Aims Pulmonary hypertension (PHT) appears to be very common in heart failure with preserved ejection fraction but details on ...

Anteris Technologies Global Corp. aims to raise $75 million in an IPO for aortic stenosis treatment development in a growing ...

A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development ...

The global structural heart devices market is witnessing remarkable growth, driven by factors such as the rising prevalence of structural heart diseases, expanding indications for transcatheter ...

In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.

Medtronic has reported new clinical data from the study of its Evolut transcatheter aortic valve replacement (TAVR) system, ...

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.